PMID- 29921043
OWN - NLM
STAT- MEDLINE
DCOM- 20190313
LR  - 20190313
IS  - 2005-6648 (Electronic)
IS  - 1226-3303 (Print)
IS  - 1226-3303 (Linking)
VI  - 33
IP  - 5
DP  - 2018 Sep
TI  - Genetic markers of severe cutaneous adverse reactions.
PG  - 867-875
LID - 10.3904/kjim.2018.126 [doi]
AB  - Adverse drug reactions can cause considerable discomfort. They can be 
      life-threatening in severe cases, requiring or prolonging hospitalization, 
      impeding proper treatment, and increasing treatment costs considerably. Although 
      the incidence of severe cutaneous adverse reactions (SCARs) is low, they can be 
      serious, have permanent sequelae, or lead to death. A recent pharmacogenomic 
      study confirmed that genetic factors can predispose an individual to SCARs. 
      Genetic markers enable not only elucidation of the pathogenesis of SCARs, but 
      also screening of susceptible subjects. The human leukocyte antigen (HLA) 
      genotypes associated with SCARs include HLA-B*57:01 for abacavir (Caucasians), 
      HLA-B*58:01 for allopurinol (Asians), HLA-B*15:02 (Han Chinese) and HLA-A*31:01 
      (Europeans and Koreans) for carbamazepine, HLA-B*59:01 for methazolamide (Koreans 
      and Japanese), and HLA-B*13:01 for dapsone (Asians). Therefore, prescreening 
      genetic testing could prevent severe drug hypersensitivity reactions. Large-scale 
      epidemiologic studies are required to demonstrate the usefulness and 
      cost-effectiveness of screening tests because their efficacy is affected by the 
      genetic differences among ethnicities.
FAU - Jung, Jae-Woo
AU  - Jung JW
AD  - Department of Internal Medicine, Chung-Ang University College of Medicine, Seoul, 
      Korea.
FAU - Kim, Jae-Yeol
AU  - Kim JY
AD  - Department of Internal Medicine, Chung-Ang University College of Medicine, Seoul, 
      Korea.
FAU - Park, In-Won
AU  - Park IW
AD  - Department of Internal Medicine, Chung-Ang University College of Medicine, Seoul, 
      Korea.
FAU - Choi, Byoung-Whui
AU  - Choi BW
AD  - Department of Internal Medicine, Chung-Ang University College of Medicine, Seoul, 
      Korea.
FAU - Kang, Hye-Ryun
AU  - Kang HR
AD  - Department of Internal Medicine, Seoul National University College of Medicine, 
      Seoul, Korea.
AD  - Institute of Allergy and Clinical Immunology, Seoul National University Medical 
      Research Center, Seoul, Korea.
LA  - eng
GR  - Ministry of Food and Drug Safety/International
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20180622
PL  - Korea (South)
TA  - Korean J Intern Med
JT  - The Korean journal of internal medicine
JID - 8712418
RN  - 0 (Genetic Markers)
RN  - 0 (HLA-B Antigens)
SB  - IM
MH  - *Drug Eruptions/genetics
MH  - *Genetic Markers
MH  - *HLA-B Antigens/genetics
MH  - Humans
MH  - Pharmacogenetics
PMC - PMC6129640
OTO - NOTNLM
OT  - Drug hypersensitivity syndrome
OT  - HLA antigens
OT  - Pharmacogenetics
OT  - Stevens-Johnson syndrome
COIS- No potential conflict of interest relevant to this article was reported.
EDAT- 2018/06/20 06:00
MHDA- 2019/03/14 06:00
PMCR- 2018/09/01
CRDT- 2018/06/20 06:00
PHST- 2018/04/06 00:00 [received]
PHST- 2018/04/12 00:00 [accepted]
PHST- 2018/06/20 06:00 [pubmed]
PHST- 2019/03/14 06:00 [medline]
PHST- 2018/06/20 06:00 [entrez]
PHST- 2018/09/01 00:00 [pmc-release]
AID - kjim.2018.126 [pii]
AID - kjim-2018-126 [pii]
AID - 10.3904/kjim.2018.126 [doi]
PST - ppublish
SO  - Korean J Intern Med. 2018 Sep;33(5):867-875. doi: 10.3904/kjim.2018.126. Epub 
      2018 Jun 22.